影响慢加急性乙型肝炎肝衰竭并发医院获得性肺炎患者预后危险因素分析*

doi:10.3969/j.issn.1672-5069.2024.06.020

摘要/Abstract

摘要： 目的分析慢加急性乙型肝炎肝衰竭(HBV-ACLF)并发医院获得性肺炎(HAP)患者预后的影响因素。方法 2018年1月～2022年12月我院诊治的HBV-ACLF并发HAP患者101例,给予内科综合和人工肝治疗。使用法国生物梅里埃VITEK MS公司生产的微生物质谱检测系统进行细菌鉴定。应用单因素和多因素Logistic回归分析影响预后的因素。结果本组HBV-ACLF并发HAP患者痰培养76例(75.3%)致病菌阳性,其中革兰氏阴性菌30株(39.5%),革兰氏阳性菌11株(14.5%)和真菌35株(46.1%);在住院(44.7±24.4)d内,死亡50例(49.5%),生存51例(50.5%);死亡组年龄、血浆乳酸、MELD评分、并发并自发性细菌性腹膜炎(SBP)和并发消化道出血占比分别为(57.3±12.1)岁、(2.7±2.1)mmol/L、(27.5±6.9)分、66.0%和42.0%,均显著高于生存组【分别为(50±12.8)岁、(1.6±0.8)mmol/L、(22.5±7.3)分、31.4%和5.9%,P＜0.05】; 多因素Logistic回归分析发现年龄(OR=1.054,95%CI:1.005～1.110)、血浆乳酸(OR=2.339,95%CI:1.255～5.031)、并发SBP(OR=6.784,95%CI:2.139～25.206)和并发消化道出血(OR=18.504,95%CI:3.973～122.636)是影响预后的独立危险因素(P＜0.05)。结论 HBV-ACLF并发HAP患者预后差,临床上应重视年龄较大和存在其他并发症的处理,以期及早干预,改善预后。

关键词: 慢加急性肝衰竭, 医院获得性肺炎, 致病菌, 预后, 影响因素

Abstract: Objective The aim of this study was to analyze influencing factors of patients with acute-on-chronic hepatitis B liver failure (HBV-ACLF) complicated by hospital-acquired pneumonia (HAP). Methods A total of 101 patients with HBV-ACLF and HAP were encountered in our hospital between January 2018 and December 2022, and all received comprehensive internal medical and liver-supporting treatment. Sputum culture and bacteria characterization were routinely performed. Univariate and multivariate Logistic regression analysis was applied to analyze independent risk factors influencing prognosis. Results Of 101 patients with HBV-ACLF and HAP, sputum obtained positive results in 76 cases (75.3%), and out of them, Gram positive pathogenic bacteria strain was found in 30 cases (39.5%), Gram negative in 11 cases (14.5%) and fungus in 35 cases (46.1%); 50 patients (49.5%) died and 51 patients (50.5%) survived during (44.7±24.4)day hospital stay; ages, plasma lactate level, model of end-stage liver disease score, percentages of concomitant spontaneous bacterial peritonitis (SBP) and gastrointestinal bleeding (GIB) in dead patients were(57.3±12.1)yr, (2.7±2.1)mmol/L, (27.5±6.9)point, 66.0% and 42.0%, all much higher than [(50±12.8)yr, (1.6±0.8)mmol/L, (22.5±7.3)point, 31.4% and 5.9%, respectively, P＜0.05] in survivals; multivariate Logistic regression analysis showed that age (OR=1.054, 95%CI:1.005-1.110), plasma lactate level (OR=2.339, 95%CI:1.255-5.031), concomitant SBP(OR=6.784, 95%CI:2.139-25.206) and GIB (OR=18.504, 95%CI:3.973-122.636) were the independent risk factors impacting prognosis (P＜0.05). Conclusion The patients with HBV-ACLF and HAP have a poor prognosis, clinicians should pay more attention to those who are elderly and with more than one complications, and take an appropriate measures in time to improve the outcomes.

Key words: Acute-on-chronic liver failure, Hospital-acquired pneumonia, Pathogens, Prognosis, Impacting factors

丘仲琼, 林建辉, 翁钘钘, 陈丽霞, 刘海钰. 影响慢加急性乙型肝炎肝衰竭并发医院获得性肺炎患者预后危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 878-881.

Qiu Zhongqiong, Lin Jianhui, Weng Yanyan, et al. Factors impacting prognosis of patients with acute-on-chronic hepatitis B liver failure complicated by hospital-acquired pneumonia[J]. Journal of Practical Hepatology, 2024, 27(6): 878-881.

参考文献

[1] Amin A, Mookerjee RP. Acute-on-chronic liver failure: definition, prognosis and management. Frontline Gastroenterol, 2020, 11(6): 458-467.
[2] Vicente A, Richard M, Rajiv J. Acute-on-chronic liver failure. N Engl J Med, 2020, 382(22): 2137-2145.
[3] Su HB, Tong JJ, Liu XY, et al. Characteristics and outcome of nosocomial bloodstream infection in patients with acute-on-chronic liver failure. Eur J Gastroenterol Hepatol, 2021, 33(1): 83-88.
[4] Chen T,Chen G, Wang GQ, et al. Expert consensus on the diagnosis and treatment of end-stage liver disease complicated by infections. Hepatol Int, 2024, 18(3): 817-832.
[5] Swarup KP, Sambedana M, Debakanta M, et al. A prospective study on the clinical significance of infections in a hospital setting among the cirrhotic patients and their outcomes. Cureus, 2023, 15(4): e37912.
[6] Javier F, Juan A, Reiner W, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut, 2018, 67(10): 1870-1880.
[7] Sumeet K A, Harshad D, John E, et al. Burden of liver diseases in the world. J Hepatol, 2019, 70(1): 151-171.
[8] Shiv KS, Ashok C, Manoj KS, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian pacific association for the study of the liver (APASL): an update. Hepatol Int, 2019, 13(4): 353-390.
[9] Stephanie P, Debora B, Charles B, et al. The global campaign to eliminate HBV and HCV infection: international viral hepatitis elimination meeting and core indicators for development towards the 2030 elimination goals. J Virus Erad, 2019, 5(1): 60-66.
[10] Wu TZ, Li J, Shao L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut, 2018, 67(12): 2181-2191.
[11] Shaheen N, Christian S. Hospitalized patients with acute pneumonia. Hosp Med Clin, 2017, 6(4): 456-469.
[12] Rafael Z, Pablo VC, Gerardo A, et al. Update of the treatment of nosocomial pneumonia in the ICU. Crit Care,2020, 24(1): 383.
[13] 中华医学会感染病学分会肝衰竭与人工肝学组;中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版).实用肝脏病杂志,2019,22(2):164-171.
[14] 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南. 实用肝脏病杂志, 2018, 21(1): 21-31.
[15] 中华人民共和国卫生部. 医院感染诊断标准(试行). 中华医学杂志, 2001, 81(5): 314-320.
[16] Richard M, Rajiv J, Pere G, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology, 2013, 144(7): 1426-1437,e1-9.
[17] Marcus MM, Tatiana R, Victoria TM, et al. Bacterial infection-triggered acute-on-chronic liver failure is associated with increased mortality. Liver Int, 2018, 38(4): 645-653.
[18] 高佳师, 许振宇, 李琎, 等. 肝衰竭继发感染的预后分析. 中华传染病杂志, 2019, 37(5): 271-274.
[19] 应高翔, 杨英, 吴凤天, 等. 慢加急性肝衰竭患者并发感染的特点及对诊断的影响. 中华临床感染病杂志, 2020, 13(2): 140-148.
[20] Rajiv J, Faouzi S, Marco P, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol, 2014, 61(5): 1038-1047.
[21] EASL Clinical Practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol, 2018, 69(2): 406-460.
[22] Jeffrey AK, Nicolaos EM. Lactic acidosis. N Engl J Med, 2014, 371(24): 2309-2319.
[23] Filipe SC, Juan GA, Eric S, et al. Lactate and number of organ failures predict intensive care unit mortality in patients with acute-on-chronic liver failure. Liver Int, 2019, 39(7): 1271-1280.
[24] Andreas D, Thomas H, Karoline R, et al. Lactate improves prediction of short-term mortality in critically ill patients with cirrhosis: a multinational study. Hepatology, 2019, 69(1): 258-269.
[25] Cai JJ, Zhang MC, HanT, et al. Characteristics of infection and its impact on short-term outcome in patients with acute-on-chronic liver failure. Medicine (Baltimore), 2017, 96(37): e8057.
[26] 李会, 苏海滨, 王永刚, 等. 乳酸对慢加急性肝衰竭合并感染患者预后的临床预测价值分析. 中华肝脏病杂志, 2023, 31(3): 300-306.
[27] Javier F, Verónica P, Jonel T, et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J Hepatol, 2019, 70(3): 398-411.
[28] Salvatore P, Virendra S, Paolo C, et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide. Gastroenterology, 2019, 156(5): 1368-1380, e10.
[29] Reiner W, Melissa L, Markus L. Pathological bacterial translocation in liver cirrhosis. J Hepatol, 2014, 60(1): 197-209.
[30] Guadalupe GT, Juan GA, Annalisa B, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American association for the study of liver diseases. Hepatology, 2017, 65(1): 310-335.
[31] Jonel T, Gu WY, Luis IS, et al. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. J Hepatol, 2020, 73(5): 1082-1091.

影响慢加急性乙型肝炎肝衰竭并发医院获得性肺炎患者预后危险因素分析^*

Factors impacting prognosis of patients with acute-on-chronic hepatitis B liver failure complicated by hospital-acquired pneumonia

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李靖, 何海滨, 李春婷, 石磊. 230例药物性肝损伤患者临床特征分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 870-873.
[2]	徐曼曼, 杨颜榕, 李珊珊, 武羽, 杨雪, 段钟平, 陈煜. 我院近10年肝衰竭患者预后变化趋势分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 874-877.
[3]	武羽, 韩宇星, 徐曼曼, 焦婧然, 杨雪, 段小宛, 陈煜. DRG付费改革背景下慢加急性肝衰竭患者费用盈亏分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 882-886.
[4]	董旭, 秦阳华, 廖威, 许明晓, 葛玲玲, 李成忠. 乙型肝炎肝硬化和慢加急性肝衰竭患者并发感染影响因素与预后分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 891-894.
[5]	张怀东, 雷宇, 周智. 失代偿期肝硬化合并肝外脓肿患者临床特点分析[J]. 实用肝脏病杂志, 2024, 27(5): 761-764.
[6]	中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27(4): 494-510.
[7]	潘劲劲, 谢琴秀, 许夕海, 郜玉峰, 李家斌. 药物性肝损伤患者血清抗核抗体阳性临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(4): 543-546.
[8]	黄静, 王菁, 方亮, 周娟, 商惠民. 血清wnt5a和LC3-Ⅱ联合MELD评分预测慢加急性乙型肝炎肝衰竭患者短期预后价值探讨^*[J]. 实用肝脏病杂志, 2024, 27(4): 551-554.
[9]	柯海霞, 张娇珍, 蒙夏玲, 许政衡, 邓丕豪. 慢加急性乙型肝炎肝衰竭患者血清CRP和sTREM-1水平变化及其预测继发感染的价值研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 555-558.
[10]	董旭, 秦阳华, 陈怡, 许明晓, 葛玲玲, 徐圣, 廖威. 预后营养指数联合全身免疫炎症指数评估乙型肝炎相关慢加急性肝衰竭患者预后临床价值研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 390-393.
[11]	倪裕丰, 倪国英, 杨志勇. 肝细胞癌组织BCLAF1和TCF3 RNA水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(3): 418-421.
[12]	梁丹丹, 江建宁, 黄锦妮, 龙诗雨, 董国珍, 苏曼, 李继娇, 滕春玲, 张萍, 苏明华. 219例药物性肝损伤患者临床特征和预后分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 210-213.
[13]	张天祺, 王敏, 杨娜, 朱怀军. 应用替加环素治疗重症感染患者DILI发生及其影响因素分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 214-217.
[14]	刘松涛, 孟庆华, 刘梅, 韩亚男, 王金环, 闾军. 急性/亚急性肝衰竭患者急性肾损伤发生率和预后分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 222-225.
[15]	何圣科, 蒲江汉, 冯海玲, 吴大平, 陈绵军, 陈辉. 肝细胞癌组织HOXC9和KIF4A表达及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(1): 84-87.